PV patients heterozygous and homozygous for JAK2V617F mutation had significantly increased levels of CD34+ cells, leukocytes, thrombocytes, and erythrocytes but reduced MCV compared to secondary erythrocytosis. This evidence concerns the gene CD34 and acquired polycythemia vera.